Literature DB >> 29307010

Prescribing of anticancer drugs in renal impairment: why can't we do better?

Emaad Abdel-Kahaar1, Oliver Zolk2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29307010     DOI： 10.1007/s00210-017-1461-5

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  8 in total

1.  Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources?

Authors:  A Khanal; R L Castelino; G M Peterson; M D Jose
Journal:  Intern Med J       Date:  2014-01       Impact factor: 2.048

2.  Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety.

Authors:  Carolin Grafe; Sabine Semrau; Alexander Hein; Matthias W Beckmann; Andreas Mackensen; Frank Dörje; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-01-02       Impact factor: 3.000

3.  Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

Authors:  Gary R Matzke; George R Aronoff; Arthur J Atkinson; William M Bennett; Brian S Decker; Kai-Uwe Eckardt; Thomas Golper; Darren W Grabe; Bertram Kasiske; Frieder Keller; Jan T Kielstein; Ravindra Mehta; Bruce A Mueller; Deborah A Pasko; Franz Schaefer; Domenic A Sica; Lesley A Inker; Jason G Umans; Patrick Murray
Journal:  Kidney Int       Date:  2011-09-14       Impact factor: 10.612

Review 4.  Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis.

Authors:  Thomas J Velenosi; Bradley L Urquhart
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-06-24       Impact factor: 4.481

Review 5.  Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.

Authors:  Nathan R Hill; Samuel T Fatoba; Jason L Oke; Jennifer A Hirst; Christopher A O'Callaghan; Daniel S Lasserson; F D Richard Hobbs
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

Review 6.  Renal insufficiency and cancer treatments.

Authors:  Vincent Launay-Vacher; Nicolas Janus; Gilbert Deray
Journal:  ESMO Open       Date:  2016-08-18

Review 7.  A survey of renal impairment pharmacokinetic studies for new oncology drug approvals in the USA from 2010 to early 2015: a focus on development strategies and future directions.

Authors:  Jim J Xiao; Jiyun S Chen; Bert L Lum; Richard A Graham
Journal:  Anticancer Drugs       Date:  2017-08       Impact factor: 2.248

8.  Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Authors: 
Journal:  Lancet       Date:  2017-09-16       Impact factor: 79.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.